drugset
drugset / Trial / NCT02929524

Intranasal Ketamine as a Sedative for Venipuncture

NCT02929524 ↗

Phase 2/3 Completed 39 enrolled Hospital de Clinicas de Porto Alegre
RandomizedParallel-groupDouble-blindTreatment

Summary

Randomized clinical trial, controlled, double-blind, parallel two-arm.

Timeline

Start
2015-04
Primary completion
2016-10
Completion
2016-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 4 mg/kg Intranasal

Indications

digestive system disorder respiratory system disorder